Art. -Nr.: HY-50879

Elacridar

(Synonyms: GF120918; GW0918; GG918; GW120918)

31 Cited Publications

Kundenbewertung

Based on 31 publication(s) in Google Scholar

Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.66%
CAS. Nr.: 143664-11-3
Formel: C₃₄H₃₃N₃O₅
Molecular Weight:563.64

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Elacridar Chemical Structure

CAS. Nr.: 143664-11-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (31)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

P-glycoprotein (Pgp), BCRP^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	EC₅₀	2 μM Compound: elacridar	Inhibition of Pgp measured as inhibition of [3H]vinblastine basolateral to apical transport in Caco-2 cells Inhibition of Pgp measured as inhibition of [3H]vinblastine basolateral to apical transport in Caco-2 cells	[PMID: 17064079]
Caco-2	EC₅₀	2 μM Compound: elacridar	Inhibition of human Pgp mediated [3H]vinblastine transport in human Caco-2 cells Inhibition of human Pgp mediated [3H]vinblastine transport in human Caco-2 cells	[PMID: 17936633]
Caco-2	EC₅₀	2 μM Compound: elacridar	Inhibition of human P-glycoprotein mediated [3H]vinblastine transport in human Caco-2 cells Inhibition of human P-glycoprotein mediated [3H]vinblastine transport in human Caco-2 cells	[PMID: 18257545]
Caco-2	EC₅₀	2 μM Compound: elacridar	Inhibition of human P-gp mediated [3H]vinblastine transport activity in human Caco-2 cells Inhibition of human P-gp mediated [3H]vinblastine transport activity in human Caco-2 cells	[PMID: 18276145]
Caco-2	IC₅₀	2 μM Compound: elacridar	Inhibition of ABCB1-mediated [3H]vinblastine transportation in human Caco-2 cells Inhibition of ABCB1-mediated [3H]vinblastine transportation in human Caco-2 cells	[PMID: 19053888]
CHRC5 cell line	EC₅₀	21 nM Compound: 84	Reversal of sensitivity of multidrug resistant chinese hamster ovary cell line CHRC/5 expressed as concentration that restores 50% of cytotoxic activity of 5 ug/mL toward doxorubicin Reversal of sensitivity of multidrug resistant chinese hamster ovary cell line CHRC/5 expressed as concentration that restores 50% of cytotoxic activity of 5 ug/mL toward doxorubicin	[PMID: 7608906]
HEK293	IC₅₀	0.41 μM Compound: GF-120918	Inhibition of ABCG2 expressed in HEK293 cells assessed as mitoxantrone-mediated efflux by flow cytometry Inhibition of ABCG2 expressed in HEK293 cells assessed as mitoxantrone-mediated efflux by flow cytometry	[PMID: 17317193]
MCF7	IC₅₀	0.4 μM Compound: GF-120918	Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining	[PMID: 19932960]
MDCK	IC₅₀	0.43 μM Compound: GF-120918	Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay	[PMID: 19932960]
MDCK-II	IC₅₀	0.4 μM Compound: 1	Inhibition of human Pgp overexpressed in human MDCK2-MDR1 cells assessed as inhibition of R123 efflux after 60 mins Inhibition of human Pgp overexpressed in human MDCK2-MDR1 cells assessed as inhibition of R123 efflux after 60 mins	[PMID: 21419632]
SK-OV-3	IC₅₀	8.1 μM Compound: GF-120918	Cytotoxicity against human SKOV3 cells Cytotoxicity against human SKOV3 cells	[PMID: 11754602]

In Vitro

Elacridar (0.001-1 μM; 2 h) inhibits cell viability of 786-O cells^[2].
Elacridar (5 μM; 24 h) affects P-glycoprotein and ABCG2 protein expression levels in MCF-7 and 786-O cell lines^[2].
Elacridar (5 μM; 24 h) affects ^99mTc-MIBI intracellular accumulation in MCF-7 and 786-O cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

786-O cells
Concentration:

2.5 and 5 μM
Incubation Time:

2 hours
Result:

Dose-dependently inhibited cell viability of 786-O cells and showed better inhibitory effect with sunitnib adding

Western Blot Analysis^[2]

Cell Line:

MCF-7, Caki-1, and 786-O cell lines
Concentration:

5 μM
Incubation Time:

24 hours
Result:

Dreased P-glycoprotein protein expression level in 786-O cells and increased ABCG2 protein expression level in Caki-1 cells.

Cell Viability Assay^[2]

Cell Line:

MCF-7 and 786-O cell lines
Concentration:

5 μM
Incubation Time:

24 hours
Result:

Dose-dependently increased ^99mTc-MIBI intracellular accumulation in MCF-7 and 786-O cells.

In Vivo

Elacridar (100 mg/kg; i.p. once) shows different distribution in brain and plasma^[1].
1.19 Plasma Pharmacokinetic Parameters of Elacridar in mice^[1].

	Mice PO 100 mg/kg	Mice IP 100 mg/kg	Mice IV 2.5 mg/kg
CL/F (ml/min)	2.05	33.2	0.46
Vd/F (liter)	3.5	12.3	0.17
t_1/2 (h)	20	4.3	4.4
AUC_0-inf (μg?min/ml)	1460	90.3	161.4
F	0.22	0.013	1

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

FVB wild-type mice^[1].
Dosage:

100 mg/kg
Administration:

Intraperitoneal injection; 100 mg/kg once
Result:

Showd a higher concertration in brain than plasma except at 4 h after the dose.

Chemical Information

CAS. Nr. 143664-11-3
Appearance Solid
Molecular Weight 563.64
Formel C₃₄H₃₃N₃O₅
Color Light yellow to brown
SMILES

O=C1C2=CC=CC(C(NC(C=C3)=CC=C3CCN4CC(C=C(C(OC)=C5)OC)=C5CC4)=O)=C2NC6=C1C=CC=C6OC
Synonyms

GF120918; GW0918; GG918; GW120918
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (31)

All IFIn Vivo Efficacy StudyHistological Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cell Metab

ABCG2 is an itaconate exporter that limits antibacterial innate immunity by alleviating TFEB-dependent lysosomal biogenesis. [Abstract]

2024 Mar 5;36(3):498-510.e11. PMID: 38181789
Sci Adv

BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis. [Abstract]

2023 Oct 20;9(42):eabp9530. PMID: 37851804

Elacridar purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Oct 20;9(42):eabp9530. [Abstract]

Elacridar (200 nM) increased the sensitivity of BCBM organoids to doxorubicin by immunofluorescent staining.
Clin Cancer Res

Inhibition of ID1-BMPR2 Intrinsic Signaling Sensitizes Glioma Stem Cells to Differentiation Therapy. [Abstract]

2018 Jan 15;24(2):383-394. PMID: 29208670
Cancer Lett

PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer. [Abstract]

2024 Nov 25:217355. PMID: 39603380

Elacridar purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2024 Nov 25:217355. [Abstract]

ABCB1 inhibition significantly reduced the number of 22Rv1-DR PCa cell-derived colonies compared to docetaxel treatment alone. Treatment with 2 μM Elacridar as a single agent did not impact colony growth in DR cells.
Mol Psychiatry

cAMP-mediated upregulation of HCN channels in VTA dopamine neurons promotes cocaine reinforcement. [Abstract]

2023 Sep;28(9):3930-3942. PMID: 37845497

Elacridar purchased from MedChemExpress. Usage Cited in: Mol Psychiatry. 2023 Sep;28(9):3930-3942. [Abstract]

Systemic ivabradine administration (0,3,10 mg/kg; i.p.) following Elacridar hydrochloride (5 mg/kg; i.v.; single dose), dose-dependently decreased the mean number of active lever presses and cocaine infusions under an FR2 reinforcement schedule.
Cell Death Dis

ETV7 regulates breast cancer stem-like cell features by repressing IFN-response genes. [Abstract]

2021 Jul 27;12(8):742. PMID: 34315857
Cell Death Dis

Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer. [Abstract]

2019 May 24;10(6):400. PMID: 31127087
Int J Biol Macromol

Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CLpro inhibitors. [Abstract]

2024 Feb 21;264(Pt 1):130377. PMID: 38395279
Biomed Pharmacother

Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta. [Abstract]

2020 Sep;129:110506. PMID: 32768979
Arch Toxicol

Daunorubicin and its hydroxy metabolite in cardiomyocytes: insights into cellular kinetics, toxicity, DNA damage, and dexrazoxane-induced cardioprotection. [Abstract]

2025 Jun 7. PMID: 40481868
Cell Rep

NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma. [Abstract]

2020 Jun 23;31(12):107782. PMID: 32579914
J Agric Food Chem

Improvement of the Intestinal Absorption of Dihydroquercetin (DHQ) by Flavonoids via Inhibiting P-Glycoprotein (P-gp)-Mediated Efflux in P-gp Overexpressed KB/MDR1 Cells and Caco-2 Monolayers. [Abstract]

2026 Feb 11;74(5):4823-4836. PMID: 41592218
J Agric Food Chem

Transport and Interactions of Co-incubated Bi-functional Flavonoids through Inhibiting the Function of P-Glycoprotein (P-gp) Using KB/Multidrug-Resistant (MDR) Cells and Rat Everted Gut Sacs. [Abstract]

2022 Feb 16;70(6):1923-1933. PMID: 35112564
J Agric Food Chem

Establishment and Use of Human Mouth Epidermal Carcinoma (KB) Cells Overexpressing P-Glycoprotein To Characterize Structure Requirements for Flavonoids Transported by the Efflux Transporter. [Abstract]

2019 Feb 27;67(8):2350-2360. PMID: 30688455
Eur J Med Chem

Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19. [Abstract]

2023 Nov 15:260:115721. PMID: 37598484
J Mater Chem B

Polymeric nanovesicles as simultaneous delivery platforms with doxorubicin conjugation and elacridar encapsulation for enhanced treatment of multidrug-resistant breast cancer. [Abstract]

2018 Dec 7;6(45):7521-7529. PMID: 32254754

Elacridar purchased from MedChemExpress. Usage Cited in: J Mater Chem B. 2018 Dec 7;6(45):7521-7529. [Abstract]

Elacridar hydrochloride (0.25 mg/kg; i.v.; every two days for a total of five doses). Ex vivo histological analyses of tumor sections excised from mice bearing MCF-7/ADR tumors after treatment. Nuclei were stained blue, and the extracellular matrix and cytoplasm were stained red through respectively. H&E staining images of the heart of MCF-7/ADR tumor-bearing mice after treatment. Scale bars represent 50 μM.

Elacridar purchased from MedChemExpress. Usage Cited in: J Mater Chem B. 2018 Dec 7;6(45):7521-7529. [Abstract]

Bioactivity inhibition of the P-gp protein in MCF-7/ADR cells using the immunofluorescence assay after incubation with different samples. Green fluorescence: P-gp proteins labelled with FITC-antibody; blue fluorescence: nuclei stained with DAPI. The scale bars represent 20 mm. DOX concentration if applied: 10 mg/mL; Elacridar hydrochloride concentration if applied: 0.5 mg/mL.

Elacridar purchased from MedChemExpress. Usage Cited in: J Mater Chem B. 2018 Dec 7;6(45):7521-7529. [Abstract]

Elacridar hydrochloride (0.25 mg/kg; i.v.; every two days for a total of five doses) co-delivered with DOX, exhibited a synergistic anticancer effect on multidrug-resistant MCF-7/ADR tumors in xenograft mouse models.
Crit Rev Anal Chem

A Critical Review on Advancement in Analytical Strategies for the Quantification of Clinically Relevant Biological Transporters. [Abstract]

2022;52(7):1557-1571. PMID: 33691566
Int J Mol Sci

Cisplatin Synergistically Enhances Antitumor Potency of Conditionally Replicating Adenovirus via p53 Dependent or Independent Pathways in Human Lung Carcinoma. [Abstract]

2019 Mar 5;20(5). pii: E1125. PMID: 30841620

Elacridar purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. [Abstract]

Sensitization of resistant cells to chemotherapy by Elacridar (5 μM) treatment.
Eur J Pharm Sci

Elacridar improves sunitinib efficacy in colorectal cancer models. [Abstract]

2025 Sep 1:212:107194. PMID: 40639493
Molecules

Quantitative Structure⁻Activity Relationships for the Flavonoid-Mediated Inhibition of P-Glycoprotein in KB/MDR1 Cells. [Abstract]

2019 Apr 27;24(9):1661. PMID: 31035631
Antiviral Res

Valspodar limits human cytomegalovirus infection and dissemination. [Abstract]

2021 Sep:193:105124. PMID: 34197862

Elacridar purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2021 Sep:193:105124. [Abstract]

Elacridar (0-33.34 μM, 72 h) do not induce cell toxicity by MTT assay.
J Biol Chem

p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells. [Abstract]

2022 Sep;298(9):102353. PMID: 35944584
Sci Rep

Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations. [Abstract]

2021 Jul 22;11(1):14948. PMID: 34294753
J Drug Target

Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer. [Abstract]

2016;24(5):441-9. PMID: 26373825

Elacridar purchased from MedChemExpress. Usage Cited in: J Drug Target. 2016;24(5):441-9. [Abstract]

Cells are co-treated with 5 μM of free LY139481 or an equivalent dose of SMA-LY139481 and either vehicle control (0.01% DMSO), Elacridar (1 μM), KO143 (5 μM), Valspodar (1 μM) or a combination of efflux inhibitors for 6 h.
Chem Res Toxicol

Inhibitory Effects of Alkaloids on BCRP Implicated in Reversing Multidrug Resistance: A Case Example of Enhancing Temozolomide Cytotoxicity. [Abstract]

2025 Aug 12. PMID: 40793827
Food Chem Toxicol

Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells. [Abstract]

2021 Sep:155:112381. PMID: 34217736
EJNMMI Res

The effect of radiation exposure on multidrug resistance: in vitro and in vivo studies using non-small lung cancer cells. [Abstract]

2015 Mar 17:5:11. PMID: 25853017
Biomed Res Int

A Novel Cryptococcal Meningitis Therapy: The Combination of Amphotericin B and Posaconazole Promotes the Distribution of Amphotericin B in the Brain Tissue. [Abstract]

2020 Nov 29;2020:8878158. PMID: 33313322
Xenobiotica

The metabolic activation of and platelet response to vicagrel vary with P-glycoprotein deficiency, rather than P-glycoprotein inhibition, in mice. [Abstract]

2024 Aug 10:1-15. PMID: 39126503
Preprints

2024 Jun 19.
Hong Kong Polytechnic University

2022 Oct.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 5 mg/mL (8.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7742 mL

8.8709 mL

17.7418 mL

5 mM

0.3548 mL

1.7742 mL

3.5484 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.67 mg/mL (2.96 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.5 mg/mL (0.89 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 0.25 mg/mL (0.44 mM); Clear solution

Protocol 4

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: 0.25 mg/mL (0.44 mM); Suspended solution; Need ultrasonic

Protocol 5

Add each solvent one by one: 1% DMSO 99% Saline

Solubility: 0.05 mg/mL (0.09 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sane R, et al. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos. 2012 Aug;40(8):1612-9. [Content Brief]

[2]. Sato H, et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Eur J Pharmacol. 2015 Jan 5;746:258-66. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7742 mL	8.8709 mL	17.7418 mL	44.3546 mL
DMSO	5 mM	0.3548 mL	1.7742 mL	3.5484 mL	8.8709 mL

Elacridar

31 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Elacridar

Membrane Transporter/Ion Channel Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Elacridar

Biologische Aktivität

Chemical Information

Publications (31)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Elacridar

Membrane Transporter/Ion Channel Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Elacridar

Biologische Aktivität

Chemical Information

Publications (31)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Elacridar Related Classifications

HY-50879 Related Classifications